ImmunityBio, Inc. (IBRX) Stock Forecast
Data as of May 3, 2026Healthcare · Current price $7.11 (0.00%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 4, 2026 | Edward Tenthoff | Piper Sandler | $12.00 | +68.9% |
| Jan 10, 2025 | Justin Zelin | BTIG | $6.00 | -15.6% |
| Aug 3, 2022 | Kelly Shi | Jefferies | $8.00 | +12.6% |
Top Analysts Covering IBRX
IBRX vs Sector & Market
| Metric | IBRX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 24 | 8 | 18 |
| Target Upside | +90.0% | +1150.2% | +14.9% |
| P/E Ratio | -19.60 | 6.89 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $205M | $209M | $214M | 4 |
| 2027-03-31 | $115M | $124M | $135M | 1 |
| 2027-06-30 | $121M | $131M | $142M | 2 |
| 2027-09-30 | $124M | $133M | $145M | 2 |
| 2027-12-31 | $134M | $144M | $157M | 1 |
| 2028-03-31 | $301M | $325M | $354M | 1 |
| 2028-06-30 | $314M | $339M | $369M | 1 |
| 2028-09-30 | $314M | $339M | $369M | 1 |
| 2028-12-31 | $326M | $352M | $383M | 1 |
| 2029-12-31 | $1.53B | $2.18B | $3.00B | 2 |
| 2030-12-31 | $2.60B | $3.69B | $5.08B | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.27 | $-0.26 | $-0.25 | 3 |
| 2027-03-31 | $-0.02 | $-0.02 | $-0.02 | 1 |
| 2027-06-30 | $-0.01 | $-0.01 | $-0.01 | 1 |
| 2027-09-30 | $-0.02 | $-0.02 | $-0.01 | 1 |
| 2027-12-31 | $-0.01 | $-0.01 | $-0.01 | 1 |
| 2028-03-31 | $0.10 | $0.11 | $0.12 | 1 |
| 2028-06-30 | $0.13 | $0.14 | $0.16 | 1 |
| 2028-09-30 | $0.12 | $0.13 | $0.15 | 1 |
| 2028-12-31 | $0.12 | $0.13 | $0.15 | 1 |
| 2029-12-31 | $0.67 | $1.09 | $1.62 | 1 |
| 2030-12-31 | $1.20 | $1.96 | $2.92 | 1 |
Frequently Asked Questions
What is the analyst consensus for IBRX?
The consensus among 24 analysts covering ImmunityBio, Inc. (IBRX) is Buy with an average price target of $13.50.
What is the highest price target for IBRX?
The highest price target for IBRX is $12.00, set by Edward Tenthoff at Piper Sandler on 2026-03-04.
What is the lowest price target for IBRX?
The lowest price target for IBRX is $6.00, set by Justin Zelin at BTIG on 2025-01-10.
How many analysts cover IBRX?
24 analysts have issued ratings for ImmunityBio, Inc. in the past 12 months.
Is IBRX a buy or sell right now?
Based on 24 analyst ratings, IBRX has a consensus rating of Buy (2.00/5) with a +90.0% upside to the consensus target of $13.50.
What are the earnings estimates for IBRX?
Analysts estimate IBRX will report EPS of $-0.26 for the period ending 2026-12-31, with revenue estimated at $209M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.